Fusion Antibodies PLC
LSE:FAB
Balance Sheet
Balance Sheet Decomposition
Fusion Antibodies PLC
Current Assets | 1.8m |
Cash & Short-Term Investments | 487k |
Receivables | 797k |
Other Current Assets | 524k |
Non-Current Assets | 250k |
PP&E | 250k |
Current Liabilities | 554k |
Accounts Payable | 537k |
Other Current Liabilities | 17k |
Non-Current Liabilities | 50k |
Long-Term Debt | 30k |
Other Non-Current Liabilities | 20k |
Balance Sheet
Fusion Antibodies PLC
Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash & Cash Equivalents |
0
|
0
|
0
|
4
|
2
|
2
|
3
|
2
|
0
|
|
Cash Equivalents |
0
|
0
|
0
|
4
|
2
|
2
|
3
|
2
|
0
|
|
Total Receivables |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
Accounts Receivables |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
Total Current Assets |
0
|
1
|
1
|
6
|
3
|
3
|
5
|
4
|
2
|
|
PP&E Net |
0
|
0
|
0
|
1
|
2
|
1
|
1
|
1
|
0
|
|
PP&E Gross |
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
0
|
|
Accumulated Depreciation |
1
|
1
|
1
|
1
|
0
|
2
|
2
|
3
|
3
|
|
Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Long-Term Assets |
0
|
1
|
1
|
1
|
1
|
2
|
0
|
0
|
0
|
|
Total Assets |
0
N/A
|
2
+404%
|
2
+15%
|
7
+234%
|
6
-13%
|
6
-3%
|
6
-3%
|
5
-16%
|
2
-58%
|
|
Liabilities | ||||||||||
Accounts Payable |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Current Liabilities |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Liabilities |
0
N/A
|
0
+104%
|
0
+9%
|
1
+41%
|
1
+40%
|
1
+38%
|
1
-12%
|
1
+14%
|
1
-24%
|
|
Equity | ||||||||||
Common Stock |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
Retained Earnings |
7
|
5
|
5
|
1
|
0
|
1
|
4
|
5
|
8
|
|
Additional Paid In Capital |
6
|
6
|
6
|
5
|
5
|
5
|
8
|
8
|
8
|
|
Total Equity |
0
N/A
|
1
+761%
|
2
+17%
|
7
+285%
|
5
-19%
|
5
-10%
|
5
-1%
|
4
-22%
|
1
-70%
|
|
Total Liabilities & Equity |
0
N/A
|
2
+404%
|
2
+15%
|
7
+234%
|
6
-13%
|
6
-3%
|
6
-3%
|
5
-16%
|
2
-58%
|
|
Shares Outstanding | ||||||||||
Common Shares Outstanding |
22
|
22
|
22
|
22
|
22
|
22
|
26
|
26
|
26
|